Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
Wednesday 26 August 2015 12:25 pm

Researchers discover a way to “switch off” diseased cancer cells

By: Clara Guibourg

Add as a preferred source on Google

US scientists have managed to “switch off” cancer cells, programming them back to normal cells in a breakthrough they hope may lead to reversing tumour growth.

A team of researchers from Mayo Clinic in Florida managed to stop cancerous cells’ abnormal growth rate, retraining them to stop reproducing and die off like a regular cell in a procedure which turned aggressive tumours into benign growths.

The researchers, whose findings were published in the journal Nature Cell Biology, showed some particularly aggressive lung and breast cancer tumours responded surprisingly well.

Panos Anastasiadis, the senior researcher behind the study, said: "We should be able to re-establish the brakes and restore normal cell function."

The brakes work by injecting "microRNA" directly into tumours, which turns cancerous cells to normal ones.

The researchers hastened to add this isn’t a magic bullet giving us a cure for cancer overnight. This breakthrough has still only been tested on cells in labs, but they're hopeful this unexpected discovery will lead to better treatments in which cancer can be quite literally “switched off”.

It represents an unexpected new biology that provides the code, the software for turning off cancer.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Tech

Trending Articles

  • A £3bn reckoning that will reshape buy now, pay later

  • Government accelerates social media crackdown with midnight curfews

  • Bank of England governor opens door to ‘simplifying’ financial rulebook

  • First Trust Global Portfolios Management Limited Announces Distribution for certain sub-funds of First Trust Global Funds ICAV

  • Alkermes to Report Second Quarter Financial Results on July 28, 2026

More from City PM

  • Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

    Business Wire
  • Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma

    Business Wire
  • StatLab Launches CytoPath Disc, Advancing Standardized Cell Block Preparation Worldwide

    Business Wire
  • morph Launches the World’s First Shapeshifting Soft Robotics Cells Platform to Bring Physical AI into Real-World Applications

    Business Wire
  • Molecular Instruments Advances Automated Multiplex Tissue Research with HCR™ Gold IF on the BOND RX Research Staining Instrument

    Business Wire
  • Dr Mom Hand Unveils Phyto-Resonance®

    Business Wire
  • Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform

    Business Wire
  • Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy · Facebook